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Prolactin receptor (PRLR), a type-1 cytokine receptor, is overexpressed in a number of cancer types. It has
attracted much attention for putative pro-oncogenic roles, which however, remains controversial in some ma
lignancies. In this study, we reported the localization of PRLR to the Hodgkin’s and Reed-Sternberg (HRS) cells of
Hodgkin’s lymphoma (HL), a neoplasm of predominantly B cell origin. Immunohistochemistry performed on 5μm thick FFPE sections revealed expression of PRLR in HRS cells. Cellular immunofluorescence experiments
showed that the HL-derived cell lines, Hs445, KMH2 and L428 overexpressed PRLR. The PRLR immunofluo
rescent signal was depleted after treating the cell lines with 10 μM of siRNA for 48 h. We also tested whether
PRLR is involved in the growth of HL, in vitro. One-way analysis of variance (ANOVA) on cell growth data obtain
from WST-1 cell proliferation assay and trypan blue exclusion assay and hemocytometry showed that siRNAdepletion of PRLR expression resulted in decreased growth in all three cell lines. These results offered only a
short insight into the involvement of PRLR in HL. As a result, further investigation is required to decipher the
precise role(s) of PRLR in the pathogenesis of HL.

1. Introduction
Overexpression of hormone receptors have been reported for a
number of cancer types, a phenotype that is suspected disease in
development and progression. One such receptor is the prolactin re
ceptor (PRLR), a type-1 cytokine receptor, although its putative prooncogenic roles remain controversial in some malignancies. Over
expression of PRLR has been reported for a growing list of cancer types
including cancers of the ovaries (Sundaram et al., 2017), cervix
(Lopez-Pulido et al., 2013), breasts (Hachim et al., 2016) prostate
(Sackmann-Sala et al., 2014), colon and rectum (Harbaum et al., 2010).
In some cancers PRLR overexpression is associated with an adverse
prognosis (Shemanko, 2016; Taylor et al., 2010). Among lymphomas,
there is only a paucity of information of PRLR expression. PRLR
expression has been reported for rat Nb2 T lymphoma cells (Shiu et al.,
1983) and a limited number of human non-Hodgkin’s lymphoma (NHL)
cell lines, including Daudi cells (Matera et al., 2000). PRL, one of the
cognate ligands for PRLR, appears to be non-mitogenic to PRLR-positive

NHL cell lines (Matera et al., 2000).
Hodgkin’s lymphoma (HL) is a unique B-cell neoplasm characterized
by giant mononuclear Hodgkin’s and multi-nuclear Reed-Sternberg
(HRS) cells, which make up less than 1% of the tumor. Previous studies
showed activated signal transducer and activator transcription 5
(STAT5) in HRS cells of a subsets of HL patients (Martini et al., 2008)
and in vitro experiments showed that activation of STAT5 resulted from
IL-21 interaction with IL-21 R (Scheeren et al., 2008). PRLR activities
are mediated via JAK2/STAT5 signaling. However, the current status of
PRLR in HL is largely unknown. Thus, this report gives a brief insight
into involvement of PRLR in HL. Immunohistochemistry (IHC) analyses
using two different primary antibodies (an anti-mouse PRLr-ECD– mAb
1A2B1 and and anti-rabbit PRLR– pAb H-300) showed strong PRLR
staining in the HRS cells in clinical specimen examined. PRLR immu
nofluorescent signal detected in cell lines stained with mAb 1A2B1
antibody, was depleted after treatment with 10 u M of siRNA for 48 h.
We also tested whether PRLR is involved in the growth of HL, in vitro.
WST-1 cell proliferation assay and trypan blue exclusion assay and
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hemocytometry showed that siRNA-knockdown of PRLR expression
resulted in decreased growth in all lines. To the best of our knowledge,
this is the first report of PRLR expression in HL. Given reports of
pro-oncogenic roles of PRLR, further research is warranted to gain in
sights into the role of PRLR in pathogenesis of HL.

permeabilized with 0.1 % PBS-TX100 (Triton X-100 purchased from
Sigma–Aldrich, MO, US, cat. #: T9284) for 30 min then blocked for
30 min in 1% normal goat serum followed by incubation in primary
antibody (mAb 1A2B1) diluted 1:400 in blocking buffer for 1 h. Stained
cells were mounted in ProLong Gold anti-fade reagent containing DAPI
(Life Technologies, Carlsbad; CA, USA, cat. #: P36931) and images were
captured with a CoolSNAP HQ2 CCD camera (Cool SNAP EZ, Photo
metrics, Tucson; AZ, USA) coupled to a Nikon Ti Eclipse inverted mi
croscope (Melville, NY, USA).

2. Methods and materials
2.1. Cell lines and cell cultures
The human HRS-derived cell lines KMH2 and L428 were obtained
from the German Collection of Microorganisms and Cell Cultures
(DSMZ), Department of Human and Animal Cell Cultures, Braunsch
weig, Germany in April 2017. Hs445 was obtained from the American
Tissue and Cell Collection –ATCC— (Manassas; VA, USA) in March
2017. L428 and KMH2 were cultured in RPMI 1640 medium supple
mented with 10 % heat-inactivated fetal bovine serum (FBS) [Gibco,
Gaithersburg; MD, USA cat. #: 10437028, lot #: 1623737], 1% Lglutamine (Thermo Fisher Scientific, Waltham; MA, USA, cat#: 25030081) and penicillin/streptomycin (Thermo Fisher Scientific, cat #:
15140148). Culture media Hs445 were similar but contained 20 % heatinactivated FBS. Cells used in these experiments were from early passage
(L428 and KMH2 passage 3, and Hs445, passage 4) and they were
treated for mycoplasma and subsequently tested negative as described
by Uphoff et al. (1992, 2002). All cells were maintained in a humid
environment of 5% CO2 at 37 ◦ C.

2.4. RNA isolation, cDNA, and qPCR
Total RNA was isolated by Trizol (Life Technologies, Carlsbad; CA,
USA, cat. # 155960218) according manufacture instructions. cDNA was
prepared by ProtoScript® II First Strand cDNA Synthesis Kit (New En
gland BioLabs, Rowley; MA, USA, cat. #: E6300S) according manufac
turer’s instructions, from 50 ng of RNA per reaction. For qPCR, each
reaction consisted of 10 ng cDNA, 10 mM primers and 10 μl 2X SYBR
GreenER™ qPCR SuperMix (Life Technologies, cat. #: 11761-100).
Reactions were carried out in a MicroAmp Fast Optical 96-Well Reac
tion Plate on a BioRad Icycler Thermal Cycler. The reaction was per
formed using the standard mode (initial denaturation at 95 ◦ C for 10 min
followed by 40 cycles of 95 ◦ C for 15 s and 60 ◦ C for 1 min). Each qPCR
reaction was done in triplicate. The amount of target mRNA was
normalized to the expression levels of the housekeeping gene GAPDH.
GAPDH primer pair were 5′ -cat ggc ctc caa gga gta ag-3′ and 5′ -agg ggt
ctac atg gca act g-3′ for forward and reverse sequences, respectively, and
those for PRLR were 5′ -tggtctgaaggggtcaatc-3′ and 5′ -cccca
gagctaaactgcaac-3′ for forward and reverse sequences, respectively. The
ΔΔCt method was used to calculate the fold-change relative to controls.
For detection of PRL in parental cell lines by qPCR, the primer for
ward and reverse sequences were 5′ - cat cat cag ctg cca cac -3′ and 5′ - cca
cgt act tcg gtg gac cag -3′ , respectively.

2.2. Immunohistochemistry
Tissue sections used in this study were purchased from OriGene
Technologies (Rockville; MD, USA) and from US BioMax (Derwood; MD,
USA). These companies provided documentation regarding approval of
tissue for clinical observation. Also, our institution does not require IRB
approval for studies on tissues procured from commercial sources. IHC
was carried out on xylene-dewaxed, degraded alcohol (100, 80, 70, 50
%), PBS (Thermo Fisher Scientific, MA, USA, cat. #: 10010023)-rehy
drated, 5-μm FFPE tissue sections, as described by Gharbaran et al.
(2019) with minor modifications. Endogenous peroxidases were
quenched by incubating the sections in 3% H2O2 solution in PBS for
10 min followed by rapid washes in PBS at room temperature. Section
were blocked at room temperature for 2 h with 1% BSA containing 5%
normal goat serum (Sigma—Aldrich, Saint Luis; MO, USA, cat. #:
G9023) in PBS, followed by overnight incubation at 4 ◦ C, in either a
mouse monoclonal anti-PRLr-ECD antibody (mAb clone 1A2B1) [Invi
trogen, Carlsbad; CA, USA—cat. #: 359200, lot #: 1529262A], diluted
1:100 or a rabbit polyclonal anti-PRLR antibody (pAb H-300) [Santa
Cruz Biotechnology, Dallas; TX, USA—cat. #: sc-20922, lot #: J1910,
clone H-300] diluted at 1:200. Signal detection was carried out using an
LSAB kit according to the manufacturer’s instructions (Agilent DAKO,
Santa Clara; CA, USA, cat. #: K0672). The sections were counterstained
with Gill’s hematoxylin (Vector Labs, Burlington; ON, Canada, cat. #:
H-3401) for 22 s and immediately washed in tap water before mounting
with VectaMount aqueous mounting media (Vector Labs, cat. #:
H-5501). Photomicrographs of stained tissues were generated with a
Leica MC190 HD Camera coupled to a Leica DM2500 microscope (Leica
Microsystems, Richmond Hill; ON, Canada). Preparation of negative
controls follows all steps except without incubation in primary antibody.

2.5. siRNA knockdown of PRLR expression
1 × 105 cells/mL cultured in 24-well plates overnight were treated
with 10 μM of siRNA to PRLR (Dharmacon, CO, USA, cat #: L-00630400-0005–ON-TARGETplus SMARTpool) for 48 h. In brief, siRNA was
complexed with Lipofectamine RNAiMax (Invitrogen, cat. #: 13778075;
lot #: 2018673) in Opti-MEM reduced serum media (Gibco, cat. #:
31985070; lot #: 2003883) in 1 x siRNA buffer (Dharmacon, cat #: B002000-UB-100), before applying to cultured cells. The sequence of
siRNAs included in the ON-TARGETplus SMARTpool from Dharmacon,
consists of the following sequences: CCGCUAAACCCUUGGAUUA
(siRNA J-006304-07), UCAGAUACCUAGUGACUUC (siRNA J-00630408), CACCAUCACUUGAACAGAA (siRNA J-006304-09), and GCAU
GAAUGUCCAGACUAC (siRNA J-006304-10). In these experiments,
control cells were treated with scrambled, non-targeted siRNA
(NT_siRNA) (OriGene Technologies, cat #: SR30004).
2.6. WST-1 cell proliferation assay
1 × 105 cells/mL plated in 96-well plates overnight and treated with
10 μM each of PRLR siRNA for 48 h were incubated in indicated culture
conditions. Cell growth was assessed with WST-1 cell proliferation assay
(Roche, Branchburg; NJ, USA, cat #: 11644807001, lot #: 14310400),
according to manufacturer’s instructions and as described by Gharbaran
et al. (2019). Absorbance was read at 450 nm on a Synergy H1 Hybrid
microplate reader (BioTek Instruments, Winooski; VT, USA). Cell
growth (in percentages, %) was computed as a ratio of either the
absorbance (A450) of PRLR_siRNA or NT_siRNA-treated and absorbance
(A450 nm) of untreated control (A450 nm).

2.3. Cellular immunofluorescence
Cellular immunofluorescence steps were similar to those for IHC
with some modifications. Cells were adhered to poly-D lysine (SigmaAldrich, MO, USA cat. #: 27964-99-4) coated number 1 coverslips for
30 min in a humid chamber at 37 ◦ C in 5 % CO2, rinsed 1 × with PBS
then fixed for 20 min with 3.7 % paraformaldehyde (Electron Micro
scopy Sciences 15710, Hatfield; PA, USA). Fixed cells were
2
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2.7. Trypan Blue exclusion assay and automated hemocytometry

reflecting cell growth were presented as standard error of the mean
(SEM) derived from triplicates. Analysis of variance (ANOVA) and F
statistics were used to determine differences between the means as
defined by p < 0.05. Each experiment was repeated at least three times.

Trypan blue exclusion assay was carried out using EVE Automated
Cell Counter (NanoEntek, Guro-gu; Seoul, South Korea) according to
manufacturer’s instructions. In brief, 10 μl of cell suspension was mixed
with 10 μl 0.4 % trypan blue then loaded into counting chamber.

3. Results

2.8. Mapping of siRNA to putative PRLR isoforms

3.1. Antibodies

We used a bioinformatics approach to the association of each siRNA
with specific PRLR isoforms. To do this, we BLAST each of the manu
facturer’s-derived siRNA sequence against publicly available human
nucleotide sequences. The list of output for each siRNA was manually
searched using the “Command + F” search function on an Apple Mac
book Air (Early 2014), using search terms related to PRLR isoforms:
transcript variant, delta S1, truncated, intermediate isoform, short iso
forms, etc.

The antibodies used in our study, mAb 1A2B1 and pAb H-300, were
among six commercial antibodies evaluated for specificity to human
PRLR expression in breast cancer (Galsgaard et al., 2009). Although both
mAb 1A2B1 and pAb H-300 produced better IHC staining than the other
antibodies tested, the authors determined that 1A2B1 was more useful
for IHC applications. Such evaluation is critical for accuracy in clinical
diagnosis. The mAb 1A2B1 antibody recognize the ectodomain portion
of the PRLR protein and pAb H-300 antibody was generated against an
epitope corresponding to amino acids 323–622 mapping at the C-ter
minus of the human PRLR, as per manufacturer’s information and
Galsgaard et al. (Galsgaard et al., 2009).
Because there is little or no information about the evaluation of these
antibodies in lymphoma, we had to determine the optimal dilution of

2.9. Statistical analyses
Data analyses were performed using SAS 9.1.3 (SAS Institute Inc.,
Cary; NC, USA) and StatView 5 (SAS Institute Inc.). Absorbance data

Fig. 1. Tissue and cell line expression of PRLR.
A–B. IHC detection of PRLR in HRS cells using
mAb 1A2B1 and pAb H-300, respectively.
C-E. Immunofluorescence detection of PRLR
expression using mAb 1A2B1, in HL-derived cell
lines Hs445, KMH2 and L428, respectively.
In A and B, negative controls are presented in
left panels and arrows in right panels point to
representative classic HRS cells. Scale bar
=100 μm.
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each for IHC and ICC. The optimal dilution of antibodies used for either
IHC or ICC were determined via serial dilution. From this titration
process, we determined that mAb 1A2B1 works optimally at 1:400 and
1:100 dilution for ICC and IHC respectively. Similar analyses resulted in
application of pAb H-300 at 1:200 dilution for IHC.

expression of the protein (Fig. 2a-c). In these experiments, the Ct values
for PRLR in parental Hs445 were 24.19, 24.97, 23.81, for KMH2 these
values were 25.18, 23.97, 24.91, and for L428, 24.58, 24.69, 24.91.
These values were comparable to those generated from cells treated with
NT_siRNA and from cells treated with lipofectamine reagent alone.
One-way ANOVA on WST-1 cell proliferation data showed statisti
cally significant difference in mean cell growth between NT_siRNA and
PRPL_siRNA treatment for each cell line of Hs445 (p < 0.02), KMH2
(p < 0.001) and L428 (p < 0.001) [Fig. 2d]. Similar results were also
observed for trypan blue exclusion assay and hemocytometry: Hs445
(p < 0.008) KMH2 (p < 0.005) and L428 (p < 0.002) [Fig. 2e]. These
results indicated that PRLR may be involved in growth of HL.

3.2. Expression of PRLR in primary Hodgkin’s and Reed-Sternberg cells
and HL cell lines
We used the mAb 1A2B1 and pAb H-300 antibodies to study the
expression of PRLR on histological sections of HL. PRLR positivity was
seen in all clinical specimen (n = 6 for each of mAb 1A2B1 and pAb H300). The HRS cells were among the cells that overexpressed PRLR
(Fig. 1a-b). These cells showed similar levels of expression of PRLR
across clinical specimen for the respective antibody used. However, the
staining with mAb 1A2B1 appeared stronger. PRLR staining in HRS cells
appeared to be localized to the cytoplasm and the cell membrane.
Immunofluorescent staining using the mAb 1A2B1 showed expres
sion of PRLR in all three HL-derived cell lines (Hs445, KMH2, L428)
studied (Fig. 1c-e). This antibody detected cell membrane and cyto
plasmic PRLR expression in Hs445, but predominantly cell membrane
PRLR signal for KMH2 and L428 cells. A subset of these latter cells also
displayed subcellular punta, the origins of which remain unclear in these
cells in this study. However, although the puncta are relatively large,
other studies showed PRLR can undergo internalization, appearing as
bright punctate spots in confocal microscopy images (Genty et al., 1994;
Perrot-Applanat et al., 1997). Every cell within each viewing field
observed for each cell line appeared to express PRLR. Like the primary
HRS cells, cell membrane expression of PRLR appeared robust among
cell lines.

3.5. Expression of PRL by HL cell lines
Although PRL has been shown to be non-mitogenic to lymphoma
cells (Matera et al., 2000) PRLR_siRNA-induced decreased growth of HL
cell lines suggest a putative PRLR-dependent growth mechanism. As PRL
contained in FBS does not significantly activate human PRLR (Utama
et al., 2009) we studied HL cell lines for PRL expression using qPCR to
gain insight into a putative PRL-PRLR axis autocrine growth mechanism.
The average Ct value for each cell line was 26.82, 28.58, and 24.79 for
Hs445, KMH2, and L428, respectively. Future studies are needed to
determine whether PRL is important for growth of HL cells via PRLR
activation.
4. Discussion
The overexpression of hormone receptors has been reported for a
growing number of cancer types. Such receptors include those for
growth hormone, estrogens, androgens, and prolactin. Here, we offer
brief insights into the involvement of PRLR in HL. The IHC analyses
showed that PRLR is overexpressed by primary HRS cells, using two
different antibodies.
We also showed that PRLR is expressed by HL-derived cell lines
Hs445, KMH2, and L428, using immunofluorescent staining. As with the
primary HRS cells, robust cell membrane expression of PRLR was
detected in the cell lines and the expression pattern appeared in almost
100 % of the cells in the microscopic viewing fields of all three cell lines.
Cell line expression of PRLR was depleted with siRNA treatment, which
also reduced cell growth. In addition, qPCR showed varying levels cell
line expression of PRL, one of the cognate ligands of PRLR, indicating a
putative autocrine mechanism of cell growth, which warrants further
research.
Although not shown in our data, PRLR signaling occurs predomi
nantly via the JAK2/STAT5 signaling pathway. Therefore, PRLR may be
one of several JAK2-STAT5 dependent receptors aberrantly active in HL
(Martini et al., 2008; Scheeren et al., 2008). Activated JAK2/STAT5
mediates the action of a multiple cytokines contributing to increased
cytokine release, inflammation and pathogenesis, in HL. For example,
interleukin-21 (IL-21) which is highly expressed by HRS cells, activates
STAT5 in HL lymphomagenesis (Scheeren et al., 2008) and mediates the
recruitment of regulatory T cells (Treg) via STAT3 activation (Lamp
recht et al., 2008). Treg infiltration in the HL tumor microenvironment
may be used to predict outcome (Alvaro et al., 2005). Other putative
PRLR-dependent signaling cascades include those related to cell prolif
eration (e.g. RAS/RAF/MAPK) (Das and Vonderhaar, 1996),
anti-apoptosis (Ramirez de Arellano et al., 2015) and cell motility (e.g.
P13-K) (Maus et al., 1999). Although these signaling cascades are also
deregulated in HL (Aravinth et al., 2019; Wallentine et al., 2007),
further studies will be needed to determine if their activities are in part,
PRLR-dependent in this B cell malignancy.

3.3. Nature of siRNAs and putative PRLR isoforms in HL
Studies in breast and prostate cancers revealed that there are mul
tiple putative isoforms of the human PRLR gene (Abramicheva and
Smirnova, 2019; Griffith et al., 2016; Shemanko, 2016), presumably a
consequence of alternative splicing and in some instances a result of
mutations. As a consequence, we conducted a search to determine the
putative predicted isoforms or transcript variants associated with PRLR
siRNA used in this study. siRNA J-006304-07 (sequence:
CCGCUAAACCCUUGGAUUA) was mapped to transcript variants tran
script variant 1, 6, X1, X2, X3, X4, X5, X6, delta S1 precursor. siRNA
J-006304-08 sequence UCAGAUACCUAGUGACUUC was associated
with transcript variant transcript variant 1, 2, 3, 4, 5, 6, 7, X1, X2, X3,
X4, X5, X6, delta S1 precursor, delta 4-SF 1B, intermediate isoform,
short isoforms 1a, 1b, 1c. The predicted transcript variants for siRNA
J-006304-09 (sequence: CACCAUCACUUGAACAGAA) include tran
script variant 1, 2, 6, X1, X1, X2, X3, X4, X5, X6, delta S1 precursor,
intermediate isoform. And siRNA J-006304-10 sequence GCAUGAAU
GUCCAGACUAC appears to target transcript variant 1, 2, 3, 4, 5, 7, X1,
X2, X3, X4, X5, X6, delta S1 precursor, delta 4-SF1b truncated,
delta-4-delta 4/11 truncated, intermediate isoform, and short isoforms
1a, 1b, 1c. Intriguingly, although the siRNAs showed 100 % similarity
with the PRLR variants, transcript variant 5 reported for siRNA
J-006304-08 showed only 73 % similarity. This data suggest that each
siRNA used in the PRLR knockdown experiments may target multiple
isoforms.
3.4. siRNA knockdown of PRLR reduced cell growth
PRLR overexpression has been implicated in growth and survival of
cancer cells. Therefore, we studied whether PRLR expression influences
growth of HL, in vitro. Cells treated with 10 μM of siRNA to PRLR for
48 h showed loss of immunofluorescent signal and decreased levels of
PRLR transcripts compared to untreated or NT_siRNA controls (Hs445,
p < 0.05; KMH2, p < 0.05; L428, p < 0.007), indicating decreased
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Fig. 2. siRNA knockdown of PRLR and reduced cell growth.
A–C. siRNA treated HL cell lines Hs445, KMH2, and L428, respectively, showed decreased levels of PRLR immunofluorescence (middle panels) compare to Lip
ofectamine (LipoFec) controls (right panels). siRNA-induced decrease in PRLR expression is supported by qPCR data (right panels) for each cell line.
D–E. Cell growth curves of WST-1 and hemoctometry data, respectively. siRNA to PRLR resulted in decreased growth of all three cell lines.
Data for each experiment was obtain from triplicates. Each experiment was repeated at least three times. Error bars in graphs represent standard error.
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